Dr. Ershler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993Phone+1 240-402-1280- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2011 - 2015
- National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 2011 - 2015
- University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 2009 - 2011
- University of North Carolina HospitalsInternship, Pediatrics, 2008 - 2009
- George Washington University School of Medicine and Health SciencesClass of 2008
- Johns Hopkins University - Bloomberg School of Public HealthM.H.S., Biochemistry, Molecular Biology, 2002 - 2003
- University of MichiganBS, Biology, 1997 - 2001
Certifications & Licensure
- WI State Medical License 2010 - 2025
- MD State Medical License 2013 - 2024
- FL State Medical License 2020 - 2022
- NC State Medical License 2008 - 2022
- PA State Medical License 2016 - 2016
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 6 citationsEligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.Bindu Kanapuru, Laura L Fernandes, Andrea Baines, Rachel Ershler, Vishal Bhatnagar, Elizabeth Pulte, Thomas Gwise, Marc R Theoret, Richard Pazdur, Lola Fashoyin-Aje, N...> ;Blood. 2023 Jul 20
- Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.Andrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, Rachel Ershler, Emily Y Jen, Bindu Kanapuru, Nicholas C Richardson, Ashley Lane, Theresa Carioti, Marc R Theore...> ;Clinical Cancer Research. 2023 Aug 1
- 13 citationsFDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.Andrea C Baines, Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li, Lian Ma, Olanrewaju O Okusanya, Natalie E Simpson, Wanda Nguyen, Marc R Theoret, Ric...> ;Clinical Cancer Research. 2022 Nov 1
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: